Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis

Gabriel Reep, Roger D. Soloway

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Patients with severe alcoholic hepatitis (AH) need to be treated with specific treatment for better outcome. Currently available specific treatment modalities are use of corticosteroids or pentoxifylline. However, the response rate to these drugs is only about 50%-60%. Hence, there is an urgent need for better and more effective treatment options. Tumor necrosis factor plays an important role in the pathogenesis of AH. However, agents blocking the action of tumor necrosis factor have not been found to be effective. Rather the randomized studies evaluating these agents showed an adverse effect and more infections in treated patients. Critical role of tumor necrosis factor in hepatic regeneration explaining this contrast is discussed. Oxidative stress and inflammation derived from gut bacteria ate two main components in the pathogenesis of AH laying foundation for the role of antioxidants, probiotics, and antibiotics in the management of AH. This article reviews the current data and status of these newer agents for the treatment of AH. Of the various options available, Vitamin E and N-acetylcysteine (NAC) have shown great promise for clinical use as adjunct to corticosteroids. With these encouraging data, future well designed studies are suggested to assess Vitamin E and NAC before their routine use in clinical practice in the management of AH.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalWorld Journal of Hepatology
Volume3
Issue number8
DOIs
StatePublished - 2011

Fingerprint

Alcoholic Hepatitis
Tumor Necrosis Factor-alpha
Acetylcysteine
Vitamin E
Adrenal Cortex Hormones
Therapeutics
Pentoxifylline
Practice Management
Probiotics
Regeneration
Oxidative Stress
Antioxidants
Anti-Bacterial Agents
Inflammation
Bacteria
Liver
Infection
Pharmaceutical Preparations

Keywords

  • Alcoholic hepatitis
  • Antioxidants
  • Betaine
  • Etanercept
  • Granulocytapheresis
  • Infliximab
  • Probiotics
  • Rifaximin
  • Tumor necrosis factor-α inhibitors

ASJC Scopus subject areas

  • Hepatology

Cite this

Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis. / Reep, Gabriel; Soloway, Roger D.

In: World Journal of Hepatology, Vol. 3, No. 8, 2011, p. 211-214.

Research output: Contribution to journalArticle

@article{3fa7c5dc0cfc4e6da97edf9f389ccb52,
title = "Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis",
abstract = "Patients with severe alcoholic hepatitis (AH) need to be treated with specific treatment for better outcome. Currently available specific treatment modalities are use of corticosteroids or pentoxifylline. However, the response rate to these drugs is only about 50{\%}-60{\%}. Hence, there is an urgent need for better and more effective treatment options. Tumor necrosis factor plays an important role in the pathogenesis of AH. However, agents blocking the action of tumor necrosis factor have not been found to be effective. Rather the randomized studies evaluating these agents showed an adverse effect and more infections in treated patients. Critical role of tumor necrosis factor in hepatic regeneration explaining this contrast is discussed. Oxidative stress and inflammation derived from gut bacteria ate two main components in the pathogenesis of AH laying foundation for the role of antioxidants, probiotics, and antibiotics in the management of AH. This article reviews the current data and status of these newer agents for the treatment of AH. Of the various options available, Vitamin E and N-acetylcysteine (NAC) have shown great promise for clinical use as adjunct to corticosteroids. With these encouraging data, future well designed studies are suggested to assess Vitamin E and NAC before their routine use in clinical practice in the management of AH.",
keywords = "Alcoholic hepatitis, Antioxidants, Betaine, Etanercept, Granulocytapheresis, Infliximab, Probiotics, Rifaximin, Tumor necrosis factor-α inhibitors",
author = "Gabriel Reep and Soloway, {Roger D.}",
year = "2011",
doi = "10.4254/wjh.v3.i8.211",
language = "English (US)",
volume = "3",
pages = "211--214",
journal = "World Journal of Hepatology",
issn = "1948-5182",
publisher = "Baishideng Publishing Group",
number = "8",

}

TY - JOUR

T1 - Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis

AU - Reep, Gabriel

AU - Soloway, Roger D.

PY - 2011

Y1 - 2011

N2 - Patients with severe alcoholic hepatitis (AH) need to be treated with specific treatment for better outcome. Currently available specific treatment modalities are use of corticosteroids or pentoxifylline. However, the response rate to these drugs is only about 50%-60%. Hence, there is an urgent need for better and more effective treatment options. Tumor necrosis factor plays an important role in the pathogenesis of AH. However, agents blocking the action of tumor necrosis factor have not been found to be effective. Rather the randomized studies evaluating these agents showed an adverse effect and more infections in treated patients. Critical role of tumor necrosis factor in hepatic regeneration explaining this contrast is discussed. Oxidative stress and inflammation derived from gut bacteria ate two main components in the pathogenesis of AH laying foundation for the role of antioxidants, probiotics, and antibiotics in the management of AH. This article reviews the current data and status of these newer agents for the treatment of AH. Of the various options available, Vitamin E and N-acetylcysteine (NAC) have shown great promise for clinical use as adjunct to corticosteroids. With these encouraging data, future well designed studies are suggested to assess Vitamin E and NAC before their routine use in clinical practice in the management of AH.

AB - Patients with severe alcoholic hepatitis (AH) need to be treated with specific treatment for better outcome. Currently available specific treatment modalities are use of corticosteroids or pentoxifylline. However, the response rate to these drugs is only about 50%-60%. Hence, there is an urgent need for better and more effective treatment options. Tumor necrosis factor plays an important role in the pathogenesis of AH. However, agents blocking the action of tumor necrosis factor have not been found to be effective. Rather the randomized studies evaluating these agents showed an adverse effect and more infections in treated patients. Critical role of tumor necrosis factor in hepatic regeneration explaining this contrast is discussed. Oxidative stress and inflammation derived from gut bacteria ate two main components in the pathogenesis of AH laying foundation for the role of antioxidants, probiotics, and antibiotics in the management of AH. This article reviews the current data and status of these newer agents for the treatment of AH. Of the various options available, Vitamin E and N-acetylcysteine (NAC) have shown great promise for clinical use as adjunct to corticosteroids. With these encouraging data, future well designed studies are suggested to assess Vitamin E and NAC before their routine use in clinical practice in the management of AH.

KW - Alcoholic hepatitis

KW - Antioxidants

KW - Betaine

KW - Etanercept

KW - Granulocytapheresis

KW - Infliximab

KW - Probiotics

KW - Rifaximin

KW - Tumor necrosis factor-α inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84873884397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873884397&partnerID=8YFLogxK

U2 - 10.4254/wjh.v3.i8.211

DO - 10.4254/wjh.v3.i8.211

M3 - Article

VL - 3

SP - 211

EP - 214

JO - World Journal of Hepatology

JF - World Journal of Hepatology

SN - 1948-5182

IS - 8

ER -